Category: Pharmaceuticals
The study will evaluate the combination of NEO-PV-01 with nivolumab (anti-PD-1 therapy) in metastatic or advanced melanoma patients Neon Therapeutics Inc., an immuno-oncology company which develops neoantigen-based treatments has reportedly presented updated data that describes pathologic and immune markers related with durable clinical advantages in …
The approval resulted from reviewing the data from the phase 3 ‘DEPICT’ clinical programme and also a dedicated trial in patients in Japan AstraZeneca recently announced that Forxiga (dapagliflozin) as an oral supplement treatment to insulin for adults having type-1 diabetes has won approval from …
The clinical data would be coming from the company’s phase-2 ampreloxetine clinical trials. The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy. Theravance Biopharma, Inc., (Theravance Biopharma), a renowned diversified biopharmaceutical company, has reportedly announced the outcome of the …
Forxiga is the first oral supplement approved in Europe as an adjunct for Type-1 diabetes patients. AstraZeneca has announced that European Commission (EC) has approved its Forxiga tablets for use in Type-1 diabetes as an oral supplement to insulin in adults. Patients with Type-1 diabetes …
The latest multi-channel consumer campaign is likely to feature several QBREXZA patients Dermira Inc., a US-based biopharmaceutical company, is currently in the news for introducing a brand-new direct-to-consumer campaign known as ‘Life Unfolds’, which has been strategized to spread awareness of QBREXZA™ treatment. As per …
Zulresso will be provided through a restricted program in which a healthcare expert administers the drug in an authorized health facility Reports confirm that the U.S. Food and Drug Administration has recently approved Zulresso injection for the treatment of Post-Partum depression (PPD) in adult women. …
Hemlibra is the first new class treatment for people suffering from acute haemophilia A without factor VIII inhibitors Its approval was given on the basis of favorable results from pivotal HAVEN 3 and HAVEN 4 studies Swiss based healthcare giant Roche AG has recently announced …
The research collaboration pact is aimed at identifying unique small molecule leads for targets of interest HitGen would apply its high-grade technology platform to find unique leads for SPARC Sun Pharma Advanced Research Company (SPARC), the research arm of India-based multinational drug manufacturer Sun Pharmaceutical …
FDA authenticates study protocol, giving go-ahead for GENFIT to begin a Phase II clinical trial in pediatric NASH. Elafibranor, the foremost molecule with positive outcomes on registered endpoints in Phase 2b clinical trials in adult NASH to be assessed in pediatric NASH. A 12 week …
